Skip to content

Metabolic Inflexibility is Related to Elevated Muscle Anaerobic Glycolysis

Metabolic Inflexibility is Related to Elevated Muscle Anaerobic Glycolysis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04320264
Enrollment
100
Registered
2020-03-24
Start date
2020-03-03
Completion date
2025-12-31
Last updated
2025-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Inflexibility

Keywords

Metabolic Inflexibility, Obesity, Anaerobic glycolysis

Brief summary

The focus of this proposal is on overweight (25\>BMI\<30 kg/m2) subjects, as these individuals exhibit a high risk of becoming obese and/or developing metabolic diseases. We hypothesize that in some overweight individuals there is a metabolic program in skeletal muscle which predisposes them to the development of obesity. Findings may lead to clinical screening tools for determining risk for obesity in non-obese individuals and targeting this group for prevention.

Detailed description

Our overall hypothesis is that increased reliance on anaerobic glycolysis in muscle shifts fasting metabolism from fat towards carbohydrate utilization, which results in metabolic inflexibility and subsequent metabolic disease (i.e. obesity). To test our hypothesis, overweight subjects (BMI 25 to 30 kg/m2) will be recruited and screened for reliance on anaerobic glycolysis (resting/fasting plasma lactate concentrations). Subjects with high (top quartile) and low (bottom quartile) resting/fasting plasma lactate will be chosen. The premise of this screening is that subjects with low lactate will have high muscle aerobic substrate oxidation, while those with elevated lactate will have low muscle oxidative metabolism. Severely obese subjects will be studied as a comparator group. In aim 1 in vivo muscle lactate release and respiratory exchange ratio (RER) will be determined to investigate if subjects with high reliance on anaerobic glycolysis exhibit a shift towards carbohydrate utilization at the whole-body level. Aim 2 will test whether subjects with elevated reliance on anaerobic glycolysis in muscle are metabolically inflexible. To establish causality, aim 3 is designed to follow subjects after an intervention that shifts skeletal muscle metabolism from carbohydrate to fat utilization. Our preliminary findings indicate that bariatric surgery normalizes muscle lactate production; therefore, severely obese subjects will be studied before and after gastric bypass surgery (aim 3). The study (MetFlex) will enroll 74 adults; (Group 1) 60 overweight (BMI 25 to 30 kg/m2) males and females ages 18-50 years old and (Group 2) 14 severely obese (BMI 40 to 50 kg/m2) adult females who are scheduled for bariatric surgery. Endpoints to be investigated in the 3 specific aims. Carbohydrate/fat oxidation (RER) in the fasting condition. High lactate vs low lactate groups (aim 1). Pre-surgery vs post-surgery (aim 3) Muscle oxygen consumption (substrate oxidation) in the fasting condition. High lactate vs low lactate groups (aim 1). Pre-surgery vs post-surgery (aim 3) Muscle lactate release in the fasting condition. High lactate vs low lactate groups (aim 1). Pre-surgery vs post-surgery (aim 3) Endogenous glucose production in the fasting condition. High lactate vs low lactate groups (aim 1). Pre-surgery vs post-surgery (aim 3) Insulin sensitivity (clamp M value). High lactate vs low lactate groups (aim 1) Change in Carbohydrate/fat oxidation (RER) in response to glucose + insulin (metabolic flexibility). High lactate vs low lactate groups (aim 2) Change in muscle fat oxidation in response to high fat feeding (metabolic flexibility). High lactate vs low lactate groups (aim 2) Change in muscle oxygen consumption (substrate oxidation) in response to high fat feeding (metabolic flexibility). High lactate vs low lactate groups (aim 2) Our basic premise is that elevated fasting plasma lactate causes glucose production to be increased and that a Vicious Cori cycle is the underlying cause of the metabolic syndrome.

Interventions

Severely obese women (BMI \>40) undergo sleeve gastrectomy

Sponsors

Duke University
CollaboratorOTHER
University of Arkansas
CollaboratorOTHER
East Carolina University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* 18-50 years old * BMI of 25 - 30 kg/m2 * BMI \> 40kg/m2 * Lactate levels in top and lower 25%

Exclusion criteria

* Pregnant women * Mentally disabled * Prisoners * Smokers * Subjects with heart disease * Type 1 and 2 diabetes * Endocrine disease * Hypertension * Musculoskeletal disease * Peripheral occlusion * Hepatic disease * Have had weight fluctuations exceeding + 3% in the previous 12 months * On medications which alter carbohydrate metabolism will not be studied

Design outcomes

Primary

MeasureTime frameDescription
Change in muscle oxygen consumption (substrate oxidation) in response to high fat feeding (metabolic flexibility).Years 1-5Oxygen consumption measured by near-infrared spectroscopy (NIRS)
Change in Carbohydrate/fat oxidation (RER) in response to glucose + insulin (metabolic flexibility)Years 1-5Indirect calorimetry during glucose clamp
Change in muscle fat oxidation in response to high fat feeding (metabolic flexibility).Years 1-5Oxidation of fatty acid in muscle homogenate.
Carbohydrate/fat oxidation (RER) in the fasting condition.Years 1-5RER will be measured from indirect calorimetry
Muscle oxygen consumption (substrate oxidation) in the fasting condition.Years 1-5Muscle oxygen consumption will be measured by near-infrared spectroscopy (NIRS)
Muscle lactate release in the fasting condition.Years 1-5Muscle lactate release will be measured by microdialysis

Secondary

MeasureTime frameDescription
Endogenous glucose production in the fasting condition.Years 1-5Measured with isotopically labeled glucose
Insulin sensitivity (clamp M value).Years 1-5Measured during glucose clamp.

Countries

United States

Contacts

Primary ContactTerry Jones, PhD
joneste@ecu.edu2527446249
Backup ContactNicholas Broskey, PhD
broskeyn19@ecu.edu2527374684

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026